Global Duchenne Muscular Dystrophy Therapeutics Market Size, Status and Forecast 2020-2026

Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
Market Analysis and Insights: Global Duchenne Muscular Dystrophy Therapeutics Market
In 2019, the global Duchenne Muscular Dystrophy Therapeutics market size was US$ 961.9 million and it is expected to reach US$ 5792.4 million by the end of 2026, with a CAGR of 28.9% during 2021-2026.
Global Duchenne Muscular Dystrophy Therapeutics Scope and Market Size
Duchenne Muscular Dystrophy Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Duchenne Muscular Dystrophy Therapeutics market is segmented into Pain Management Drugs, Corticosteroids, Prednisolone, Prednisone, Deflazacort, etc.
Segment by Application, the Duchenne Muscular Dystrophy Therapeutics market is segmented into Hospitals, Clinics, Home Care Settings, etc.
Regional and Country-level Analysis
The Duchenne Muscular Dystrophy Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Duchenne Muscular Dystrophy Therapeutics market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Duchenne Muscular Dystrophy Therapeutics Market Share Analysis
Duchenne Muscular Dystrophy Therapeutics market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Duchenne Muscular Dystrophy Therapeutics business, the date to enter into the Duchenne Muscular Dystrophy Therapeutics market, Duchenne Muscular Dystrophy Therapeutics product introduction, recent developments, etc.
The major vendors include Bristol-Myers Squibb, FibroGen (US), Italfarmaco (Italy), Marathon, NS Pharma (US), PTC Therapeutics (US), Pfizer, ReveraGen BioPharma (US), Santhera Pharmaceuticals (Switzerland), Sarepta Therapeutics (US), etc.

This report focuses on the global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Duchenne Muscular Dystrophy Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)

Market segment by Type, the product can be split into

Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort

Market segment by Application, split into

Hospitals
Clinics
Home Care Settings

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Duchenne Muscular Dystrophy Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Duchenne Muscular Dystrophy Therapeutics are as follows:
History Year: 2015-2019

Base Year:

2019

Estimated Year:

2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions